Volavka J, Cooper T B
J Clin Psychopharmacol. 1987 Feb;7(1):25-30.
The studies of relationship between haloperidol plasma levels and clinical response in schizophrenia have yielded variable results. A therapeutic window for haloperidol may exist, but the evidence for it is inconsistent. Future studies of this problem using larger patient samples would permit the investigation of interactions between the clinical predictors and the haloperidol plasma levels in the determination of clinical outcome. Although the reduced haloperidol in plasma as well as the red blood cell levels of haloperidol and reduced haloperidol or ratios of the metabolite to parent compound may also be related to clinical outcome, the evidence for this relationship is very tentative. More research is needed before routine clinical monitoring of haloperidol blood levels can be recommended.
关于精神分裂症患者中氟哌啶醇血浆水平与临床反应之间关系的研究结果不一。氟哌啶醇可能存在一个治疗窗,但其证据并不一致。未来使用更大患者样本对该问题进行的研究将有助于探讨临床预测因素与氟哌啶醇血浆水平之间在决定临床结局方面的相互作用。虽然血浆中氟哌啶醇水平降低以及红细胞中氟哌啶醇水平、氟哌啶醇降低或代谢物与母体化合物的比率也可能与临床结局相关,但这种关系的证据非常不确定。在推荐对氟哌啶醇血药浓度进行常规临床监测之前,还需要更多的研究。